In February 2024, Sanofi reported several key developments: Phase 2 data showing frexalimab's potential for relapsing MS on February 15, Japan's approval of Dupixent for chronic spontaneous urticaria on February 16, board appointments proposed on February 22, FDA priority review for Dupixent's COPD treatment on February 23, and promising Phase 2 results for rilzabrutinib on February 24.